TEVA Teva- Pharmaceutical Industries margins

Relative Growth: Rel. Growth: 35

Relative Strength: Rel. Strength: 93

Relative Valuation: Rel. Valuation: 56

Relative Profitability: Rel. Profitability: 74

Gross margin

52.5%

Operating margin

9.2%

EBITDA margin

15%

Net margin

4.1%

Current Teva- Pharmaceutical Industries reports a gross margin of 52.5%, an operating margin of 9.2%, an EBITDA margin of 15%, and a net margin of 4.1%. All measured margins increased year over year, led by net margin with an increase of 5.1 percentage points.

TEVA margin history

Gross, operating, EBITDA and net margin trends

Over the last 3 years, Teva- Pharmaceutical Industries's margins averaged 50.05% gross, 5.8% operating, 12.9% EBITDA, and -0.74% net. All four current margins are above their three-year averages.

TEVA margin expansion

Year-over-year margin changes in percentage points

Gross margin expanded by 2.9 percentage points, operating margin by 3.8 percentage points, EBITDA margin by 3.4 percentage points, and net margin by 5.1 percentage points, led by net margin with an increase of 5.1 percentage points.

Gross margin expansion

2.9pp

Operating margin expansion

3.8pp

EBITDA margin expansion

3.4pp

Net margin expansion

5.1pp

TEVA Gross margin

Looking at the last 3 years, Teva- Pharmaceutical Industries had an average gross margin of 50.05%. Teva- Pharmaceutical Industries currently reports a gross margin of 52.5%, 2.5 percentage points above its three-year average. Looking back over the last 3 years, Teva- Pharmaceutical Industries's gross margin reached 52.5% at its highest point in Jun 2026 and 48.3% at its lowest in Dec 2023.

TEVA Operating margin

Over the last 3 years, Teva- Pharmaceutical Industries's operating margin averaged 5.8%. As of the latest period, Teva- Pharmaceutical Industries's current operating margin is 9.2%, which is 3.4 percentage points above its three-year average. During this period, operating margin reached a high of 13.2% in Mar 2026 and a low of -1.9% in Dec 2024.

TEVA EBITDA margin

Across the last 3 years, Teva- Pharmaceutical Industries's EBITDA margin stood at 12.9%. Compared with its three-year average, Teva- Pharmaceutical Industries's current EBITDA margin is 15% and is 2.1 percentage points above its three-year average. EBITDA margin was highest at 19% in Mar 2026 and lowest at 6.5% in Dec 2024.

TEVA Net margin

The average net margin for Teva- Pharmaceutical Industries was -0.74% over the last 3 years. The current net margin stands at 4.1%, 4.8 percentage points above its three-year average. The net margin for Teva- Pharmaceutical Industries moved between -9.9% in Dec 2024 and 9% in Mar 2026.

TEVA margin group comparison

Margins compared with peer-group, industry and sector averages

Teva- Pharmaceutical Industries's gross margin of 52.5% is below the Healthcare sector, the industry and its peers average. Compared to its Healthcare sector average of 68.3%, Teva- Pharmaceutical Industries's gross margin is 23% lower.

TEVA margin peer comparison

Compare margins with selected peers

Frequently asked questions

What is Teva- Pharmaceutical Industries's gross margin?

The current gross margin for TEVA is 52.5% as of Jun 30, 2026.

What is Teva- Pharmaceutical Industries's operating margin?

As of Jun 30, 2026, TEVA has an operating margin of 9.2%.

What is Teva- Pharmaceutical Industries's EBITDA margin?

The current EBITDA margin for TEVA is 15% as of Jun 30, 2026.

What is Teva- Pharmaceutical Industries's net margin?

The current net margin for TEVA is 4.1% as of Jun 30, 2026.

What are the average margins of TEVA?

Across the last 3 years, TEVA averaged 50.1% gross, 5.8% operating, 12.9% EBITDA, and -0.7% net.

What are the highest historical margins of TEVA?

Across the 5-year period, TEVA posted its highest margins at 52.5% gross in Jun 2026, 13.2% operating in Mar 2026, 19% EBITDA in Mar 2026, and 9% net in Mar 2026.

What are the lowest historical margins of TEVA?

In the last 5 years, the lowest margins reported by TEVA were 45.4% gross in Jun 2023, -15.4% operating in Dec 2022, -5.5% EBITDA in Dec 2022, and -16.4% net in Dec 2022.